HGWISE Career Panel: Academia to Industry


Thursday, June 3, 2021, 5:00pm to 6:00pm


Zoom - Register for Details

Interested in transitioning from academia to industry roles? Come hear from panelists in biotechs & venture capital space who are leveraging their scientific training to build impactful companies.

Thursday, June 3, 2021
5-6pm EST
Zoom link: Will be sent to RSVP'ed attendees

Hosted by Harvard Graduate Women in Science and Engineering (HGWISE). We hope to see you there!

-- Speaker Bios --

Peyton Greenside is Co-founder and CSO of BigHat Biosciences, an early-stage Bay Area startup developing an AI-first experimental platform to radically reduce the difficulty of designing antibodies and other therapeutic proteins. Peyton was an inaugural Schmidt Science Fellow, a computational biologist at the Broad Institute, a scientific founder of Valis, and holds a PhD from Stanford University (Accel Innovation Scholar), an MPhil in Computational Biology from Cambridge University (Herchel Smith Scholar), and a BA in Applied Math from Harvard.

Rachel Meyers, Ph.D. serves as the chief scientific officer at Faze Medicines. She was most recently an entrepreneur-in-residence at Third Rock Ventures (TRV), where she helped drive the creation of Faze Medicines. Rachel brings more than twenty years of drug discovery and development expertise to Faze and is an expert in the development of RNAi therapeutics. Prior to joining Faze and TRV, she served as a biotech consultant in the Greater Boston area and served as SVP Research and RNAi Lead Development at Alnylam Pharmaceuticals where she spent over 13 years. Prior to Alnylam, Rachel was a senior scientist at Millennium Pharmaceuticals. She also serves on several scientific advisory boards, consults on nucleic acid therapeutic development, is listed as an inventor on many patents and patent applications, and has numerous peer-reviewed publications. She completed her postdoctoral training at Harvard Medical School in the field of signal transduction and received her PhD from MIT in the field of in vitro transcription.

Pengpeng Li, Ph.D. joined 5AM Ventures in 2019 as a 4:59 Analyst and was promoted to Associate in 2021. Prior to joining 5AM, she was a HHMI-Helen Hey Whitney Foundation Postdoctoral Fellow at Boston Children’s Hospital and Harvard Medical School, where she studied human brain development using single-cell technologies in Christopher A. Walsh’s laboratory. Dr. Li obtained her Ph.D. in Biology from Stanford University and received HHMI International Predoctoral Fellowship to study neural development in Dr. Kang Shen’s laboratory where she graduated with the Frances Lou Kallman Award. Her work has been published in Science, Cell, Neuron, among others. She received her B.S. in Biology from Peking University. Dr. Li is based in the Boston, MA office.

Register: http://bit.ly/hgwisepanel